FAST TAT
The unrelated post just made probably answers the question. I beleive that many of the pharma companies believe that the couple week head start gives them a leg up on competing treatments. The results are available the same day as the biopsy and the molecular pathway is diagnosed so the physician has the ability to prescribe with knowledge. The periodic system updates via the internet enable the placement of targeted ads/educational information. GHDX also claims that there is a tremendous aversion in a lot of countries to shipping tissue samples outside of the country. GHDX claims that Germany, France and others have been clamoring for a point of care system.
Many countries stipulate reimbursement levels based on the test irregardless whether it is analyzed in a certified lab or at the point of biopsy using an IVD test. I believe that due to the present cost differences between IVD and NGS, this provides the opportunity for the physician or clinic to theoretically pocket a lot of the difference in cost between the cartridge cost and the reimbursement price generating nice profits for the clinic, hospital, Dr. office etc. As my previous post indicated, the cost of NGS is coming down rapidly so this price differential wundow may not exist forever. I think BCART recognizes this and that was one of the reason for their convertible offering a couple weeks ago. They want to quicken the pace of moving their tests from research only to complete registration for diagnostic purposes. This opens the system for wider usage.
FL
Market Data 
Markets 
AI
